Identification of NEK3 and MOK as novel targets for lithium
Authors
Bravo , Ana; Lucio Ortega, Héctor Elessar de; Sánchez Murcia, Pedro Alejandro; Jiménez Ruiz, Antonio; Petrone , Paula M.; [et al.]Identifiers
Permanent link (URI): http://hdl.handle.net/10017/58991DOI: 10.1111/cbdd.13487
ISSN: 1747-0277
Date
2019-02-12Affiliation
Universidad de Alcalá. Departamento de Ciencias Biomédicas; Universidad de Alcalá. Departamento de Biología de SistemasFunders
Ministerio de Economía y Competitividad
Bibliographic citation
Chemical Biology and Drug Design, 2019, v. 93, n. 5, p. 965-969
Keywords
axonal growth
bipolar disorder
GSK3B
lithium
MOK
NEK3
Description / Notes
Lithium ion, commonly used as the carbonate salt in the treatment of bipolar disorders, has been identified as an inhibitor of several kinases, including Glycogen Synthase Kinase-3ß, for almost 20 years. However, both the exact mechanism of enzymatic inhibition and its apparent specificity for certain metalloenzymes are still a matter of debate. A data-driven hypothesis is presented that accounts for the specificity profile of kinase inhibition by lithium in terms of the presence of a unique protein environment in the magnesium-binding site. This hypothesis has been validated by the discovery of two novel potential targets for lithium, namely NEK3 and MOK, which are related to neuronal function.
Project
info:eu-repo/grantAgreement/MINECO/SAF2015- 64629-C2-2-R/ES/
Document type
info:eu-repo/semantics/article
Version
info:eu-repo/semantics/publishedVersion
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
© John Wiley & Sons A/S, 2019
Access rights
info:eu-repo/semantics/openAccess
Files in this item
Files | Size | Format |
|
---|---|---|---|
Identification_Bravo_ChemBiolD ... | 941.5Kb |
|
Files | Size | Format |
|
---|---|---|---|
Identification_Bravo_ChemBiolD ... | 941.5Kb |
|
Collections
- BIOQBM - Artículos [137]